β-amyloid (Aβ) deposition is pathognomic for Alzheimer's disease (AD), but may occur in
normal elderly people without apparent cognitive effect. Episodic memory impairment is an …

Objective Elucidating the role of aggregated β‐amyloid in relation to gray matter atrophy is
crucial to the understanding of the pathological mechanisms of Alzheimer disease and for the …

Objective Assess Aβ deposition longitudinally and explore its relationship with cognition and
disease progression. Methods Clinical follow‐up was obtained 20 ± 3 months after [ 11 C]…

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer’s disease (AD) pathophysiology. While the detailed molecular mechanisms …

Background Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly from
a preclinical phase into a fully expressed clinical syndrome. We aimed to use longitudinal …

Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …

To facilitate clinical trials of disease-modifying therapies for Alzheimer’s disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease 1 , 2 , …

Objective: To compare brain β-amyloid (Aβ) burden measured with [ 11 C]Pittsburgh Compound
B (PIB) PET in normal aging, Alzheimer disease (AD), and other dementias. Methods: …

Evidence accumulated over more than 45 years has indicated that environmental stimuli
can induce craving for drugs of abuse in individuals who have addictive disorders. However, …

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, a participant of the
worldwide Alzheimer's Disease Neuroimaging Initiative (ADNI), recruited 1112 participants …